创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

去势抵抗性前列腺癌患者对雄激素受体拮抗剂耐药机制的研究进展

Resistance to Androgen Receptor Antagonists in Patients with Castration-Resistant Prostate Cancer

  • 摘要: 前列腺癌是困扰全球男性的重大癌症疾病之一,近年来发病率不断升高。雄激素受体(androgen receptor,AR)信号通路一直是前列腺癌治疗的关键通路,据此采取的包括雄激素剥夺治疗(androgen-depri-vation therapy,ADT)、AR拮抗剂等激素治疗方法仅对早期非转移性疾病明显有效,绝大部分患者晚期进展为去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC)。近年来,针对CRPC患者对AR拮抗剂耐药机制的研究取得了显著进展。通过对AR信号通路异常、AR基因突变、AR共调节因子改变等机制在CRPC患者对AR拮抗剂耐药中的作用进行综述,并对目前PCa治疗中针对AR拮抗剂的相关耐药机制进行研究,旨在为相关新型拮抗剂的研发及临床治疗方案的设计提供参考。

     

    Abstract: Prostate cancer (PCa) is a major cancer affecting men worldwide, with an increasing incidence in recent years. The androgen receptor (AR) signaling pathway has always been a key pathway in the treatment of prostate cancer, and the hormone treatments such as androgen deprivation therapy (ADT) and AR antagonists are only effective for early-stage non-metastatic disease, while the vast majority of patients progress to castration-resistant prostate cancer (CRPC) at an advanced stage prostate cancer. In recent years, significant progress has been made in research on the mechanisms of resistance to AR antagonists in CRPC patients. This article reviews the roles of abnormalities in the AR signaling pathway, AR gene mutations, and alterations in AR co-regulators in the development of resistance to AR antagonists among CRPC patients, and the current research on the resistance mechanism of AR antagonists in the treatment of PCa, aiming to provide some insight for the development of related new antagonists and the design of clinical treatment.

     

/

返回文章
返回